Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 4, 2012, Pages 458-468

  Peng, C Y ^a,c   Lai, H C ^b,c   Li, Y F ^b   Su, W P ^c   Chuang, P H ^c   Kao, J T ^c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; VIRUS DNA;

ADULT; ARTICLE; BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; SENSITIVITY AND SPECIFICITY; SUSTAINED DRUG RELEASE; TREATMENT DURATION;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; VIRAL LOAD;

EID: 84862776715     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04973.x     Document Type: Article

References (25)

1. Liaw YF, Chu CM,. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
2. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF,. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116: 829-34. (Pubitemid 38721324)
3. Liaw YF, Leung N, Kao JH, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
4. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
5. EASL. Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
6. Ayoub WS, Keeffe EB,. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2011; 34: 1145-58.
7. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al,. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51. (Pubitemid 44958517)
8. Marcellin P, Lau GK, Bonino F, et al,. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17. (Pubitemid 39296307)
9. Marcellin P, Bonino F, Lau GK, et al,. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009; 136: 2169-79.
10. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ,. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73-82. (Pubitemid 46340428)
11. Brunetto MR, Moriconi F, Bonino F, et al,. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
12. Moucari R, Mackiewicz V, Lada O, et al,. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
13. Rijckborst V, Hansen BE, Cakaloglu Y, et al,. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-61.
14. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al,. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009; 14: 1183-8.
15. Mizokami M, Nakano T, Orito E, et al,. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 1999; 450: 66-71. (Pubitemid 29206714)
16. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
17. Piratvisuth T, Lau G, Chao YC, et al,. Sustained response to peginterferon alfa-2a (40kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008; 2: 102-10. (Pubitemid 351250409)
18. Chen CJ, Yang HI, Su J, et al,. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. (Pubitemid 43042691)
19. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ,. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86. (Pubitemid 43374518)
20. Iloeje UH, Yang HI, Jen CL, et al,. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007; 5: 921-31. (Pubitemid 47161142)
21. Bonino F, Marcellin P, Lau GKK, et al,. Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705. (Pubitemid 46662938)
22. Thompson AJ, Nguyen T, Iser D, et al,. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-44.
23. Jang JW, Yoo SH, Kwon JH, et al,. Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infection. Aliment Pharmacol Ther 2011; 34: 1337-46.
24. Sung JJ, Wong ML, Bowden S, et al,. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-7. (Pubitemid 40824700)
25. Wursthorn K, Lutgehetmann M, Dandri M, et al,. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-84. (Pubitemid 44433724)